间隔经颅直流电刺激治疗重性抑郁症
这项前瞻性开放标签研究纳入30例重性抑郁症患者,接受为期2周共50次间隔经颅直流电刺激治疗,评估可行性、安全性、耐受性及初步疗效。方案可行性良好,保留率93.3%、依从率99.7%,无严重不良事件,HAM-D-17评分从基线21.3降至1周15.3和4周13.2。作者结论为方案可行、安全、耐受良好并显著减轻抑郁症状,但需假刺激对照随机试验验证。
要点
- 30例重性抑郁症患者接受2周50次间隔经颅直流电刺激,保留率93.3%、依从率99.7%。
- 无严重不良事件,最常见为刺激时轻度刺痛瘙痒感(100%)和刺激后暂时性皮肤发红(100%)。
- HAM-D-17评分从基线21.3降至1周15.3和4周13.2,MADRS呈相似趋势。
核心结论
- 该间隔经颅直流电刺激方案可行、安全、耐受良好,并导致抑郁症状显著减轻。
- 这些结果需在假刺激对照随机试验中验证。
- 未来试验纳入神经生理学测量以评估生物靶点 engagement,可能有助于理解潜在机制和发现生物标志物。
研究设计与样本
- 前瞻性开放标签研究,纳入30例重性抑郁症参与者。
- 参与者接受为期2周共50次经颅直流电刺激治疗。
- 在基线和1周、4周随访时用HAM-D-17和MADRS评估,治疗期间每日用HAM-D-6评估。
主要发现
- 方案可行性良好,保留率93.3%,依从率99.7%。
- 无严重不良事件;最常见副作用为刺激时轻度刺痛和瘙痒感(100%)及刺激后暂时性皮肤发红(100%)。
- 64.3%的参与者出现轻度刺激性接触性皮炎,多数在1周随访时消失,其余在4周随访时完全消退;该反应未限制治疗且无需特殊处理。
- HAM-D-17评分从基线均值21.3(SD=3.0)降至1周15.3(SD=6.3)和4周13.2(SD=7.1)。
- HAM-D-17测得的抑郁症状严重度随时间显著降低,MADRS观察到相似趋势;HAM-D-6评分显示应答组间重要差异,尤其在治疗后期,提示1周和4周随访间可能存在不同应答模式。
关键数值与推荐
- HAM-D-17评分从基线均值21.3(SD=3.0)降至1周15.3(SD=6.3)和4周13.2(SD=7.1)。
- 保留率93.3%,依从率99.7%。
- 64.3%的参与者出现轻度刺激性接触性皮炎。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些结果需在假刺激对照随机试验中验证。
- 未来试验需纳入神经生理学测量以评估生物靶点 engagement,可能有助于理解潜在机制和发现生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study investigated spaced transcranial direct current stimulation for major depressive disorder, focusing on feasibility. METHODS: In a prospective open-label study, 30 participants with major depressive disorder were enrolled to receive a 50-session transcranial direct current stimulation (tDCS) treatment over 2 weeks. The feasibility, safety, tolerability, and preliminary therapeutic effects of this tDCS protocol were assessed using the 17-item Hamilton Depression Rating Scale (HAM-D-17) and the Montgomery-Åsberg Depression Rating Scale (MADRS) at baseline and 1-week and 4-week follow-ups, as well as with the 6-item HAM-D (HAM-D-6) daily during treatment. RESULTS: The protocol demonstrated good feasibility, with a retention rate of 93.3% and an adherence rate of 99.7%. There were no serious adverse events. The most common side effect was a mild tingling and itching sensation during stimulation (100%) and temporary skin redness following stimulation (100%). Additionally, 64.3% of participants presented with mild irritative contact dermatitis, which had disappeared by the 1-week follow-up for most participants and completely resolved by the 4-week follow-up for the remaining cases; this was not treatment limiting and did not require specific treatment. HAM-D-17 scores decreased from a mean of 21.3 (SD=3.0) at baseline to 15.3 (SD=6.3) at 1 week and 13.2 (SD=7.1) at 4 weeks. Depressive symptom severity, as measured by the HAM-D-17, showed significant reductions over time, with similar trends observed on the MADRS. HAM-D-6 scores highlighted important differences between response groups, particularly during the later stages of treatment, suggesting a potential for differential response patterns between the 1-week and 4-week follow-ups. CONCLUSIONS: The protocol was feasible, safe, and well-tolerated and led to significant reductions in depressive symptoms. These results will need to be validated in a sham-controlled randomized trial. The inclusion of neurophysiological measures in future trials for purposes of biological target engagement might also contribute to our understanding of underlying mechanisms and biomarker discovery.
引用
- Couture M, Desbeaumes Jodoin V, Bousseau E, et al. Spaced Transcranial Direct Current Stimulation for Major Depression. Am J Psychiatry. 2025. PMID: 39876681. doi:10.1176/appi.ajp.20240083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。